AB0341 Rheumatoid Arthritis Associated Interstitial Lung Disease Progression in a Cohort of Treated to Target Patients

BackgroundInterstitial lung disease (ILD) is the most common manifestation of rheumatoid lung disease (RA-ILD). The prevalence of RA-ILD is somewhere between 10 and 50 percent, depending on the study. In analogy with Systemic Sclerosis associated ILD (SSc-ILD), high resolution computed tomography (HRCT) has become the gold standard for diagnosis of RA-ILD. Literature data describe a strong correlation between HRCT pattern of ILD and histopathological subtypes. Moreover, different systems for evaluating SSc-ILD on HRCT and several scoring methods have been proposed for RA-ILD. Because of the uncertainty of the effect of traditional DMARDs and biologic agents on the development and course of ILD in patients with RA, careful pre-treatment assessment and subsequent monitoring are required. We present the results of the follow-up to 1 year of a cohort of patients treated with DMARDs and maintained in the therapeutic target (DAS28 low disease activity or remission).ObjectivesTo evaluate the change in respiratory function and ILD HRTC score in a cohort of patients treated to target.Methods24 RA patients in DMARD monotherapy and low dose steroid (dose of prednisone